Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

General Electric Co GE

General Electric Company, doing business as GE Aerospace, is a global aerospace propulsion, services, and systems company. The Company provides jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. Its portfolio of brands includes Avio Aero, Unison, GE Additive and Dowty Propellers. Avio Aero is a GE Aerospace business which operates in the design, manufacturing, and maintenance of civil and military aeronautics subsystems and systems. Dowty Propellers manufactures integrated propeller systems, which are used in applications that range from regional airliners and military airlifters to marine hovercraft. GE Additive offers a suite of products for additive manufacturing. Unison builds advanced gas turbine components and electrical and mechanical systems throughout the world. Its services include TrueChoice commercial services, TRUEngine, on wing support, regional and business aviation, and test services.


NYSE:GE - Post by User

Post by SophiaBrownon Jun 03, 2022 3:08am
110 Views
Post# 34728615

FSD will proceed with Phase2 of FSD-201 soon after clearance

FSD will proceed with Phase2 of FSD-201 soon after clearance
FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.

<< Previous
Bullboard Posts
Next >>